Yağmur Darben Azarsız
Research Subjects
Yağmur Darben Azarsız has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Aybeniz Civan Kahve
Department of Psychiatry, Faculty of Medicine, Gazi University, Türkiye
3 shared publications - Andaç Uzdoğan
Department of Biochemistry, Ankara Bilkent City Hospital, Ankara, Turkey
2 shared publications - Erol Göka
Department of Psychiatry, University of Health Sciences, Ankara City Hospital, Ankara, Turkey
2 shared publications - Ezgi Sıla Ahi Üstün
Mamak State Hospital
2 shared publications - Hasan Kaya
University of Health Sciences, Ankara Bilkent City Hospital
2 shared publications - Nagihan Ayaz Naycı
Department of Psychiatry, Giresun Prof. Dr. A. İlhan Özdemir State Hospital, 28200, Giresun, Türkiye
2 shared publications
Latest Publications
- Open Access
- 19 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 26050
Work life balance and psychological wellbeing as correlates of quiet quitting among physicians
Physicians are exposed to persistent occupational stressors, which place them at increased risk for burnout and occupational disengagement. In the post-pandemic era, “quiet quitting” has emerged as a form of occupational disengagement characterized by psychological withdrawal while maintaining formal job roles. Understanding the mechanisms underlying this phenomenon is critical for sustaining motivation and well-being in healthcare professionals. This study aimed to investigate quiet quitting as an indicator of reduced occupational engagement among physicians and to examine its associations with work–life balance and psychological well-being within the framework of occupational motivation and burnout A cross-sectional analytical study was conducted with 426 physicians between December 2025 and February 2026. Participants completed the Work–Life Balance Scale, Psychological Well-Being Scale, and Quiet Quitting Scale. Associations were analyzed using Spearman correlation, and hierarchical multiple linear regression was performed to identify independent predictors of quiet quitting. Quiet quitting showed a moderate negative correlation with psychological well-being (r = − 0.379, p < 0.001) and positive work-to-life spillover (r = − 0.424, p < 0.001), and a positive correlation with negative life-to-work spillover (r = 0.365, p < 0.001). In regression analyses, psychological well-being (β = −0.176, p < 0.001) and positive work-to-life spillover (β = −0.281, p < 0.001) emerged as significant protective factors against quiet quitting. Additionally, medico-legal experiences and consideration of leaving the profession were associated with increased disengagement. Quiet quitting may represent a clinically relevant manifestation of reduced motivation and occupational disengagement among physicians. Our findings highlight the need for integrated interventions targeting both structural work conditions and individual psychological resources to mitigate disengagement and support sustainable workforce well-being in healthcare systems.
- 19 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 26050
Open AccessWork life balance and psychological wellbeing as correlates of quiet quitting among physicians
Physicians are exposed to persistent occupational stressors, which place them at increased risk for burnout and occupational disengagement. In the post-pandemic era, “quiet quitting” has emerged as a form of occupational disengagement characterized by psychological withdrawal while maintaining formal job roles. Understanding the mechanisms underlying this phenomenon is critical for sustaining motivation and well-being in healthcare professionals. This study aimed to investigate quiet quitting as an indicator of reduced occupational engagement among physicians and to examine its associations with work–life balance and psychological well-being within the framework of occupational motivation and burnout A cross-sectional analytical study was conducted with 426 physicians between December 2025 and February 2026. Participants completed the Work–Life Balance Scale, Psychological Well-Being Scale, and Quiet Quitting Scale. Associations were analyzed using Spearman correlation, and hierarchical multiple linear regression was performed to identify independent predictors of quiet quitting. Quiet quitting showed a moderate negative correlation with psychological well-being (r = − 0.379, p < 0.001) and positive work-to-life spillover (r = − 0.424, p < 0.001), and a positive correlation with negative life-to-work spillover (r = 0.365, p < 0.001). In regression analyses, psychological well-being (β = −0.176, p < 0.001) and positive work-to-life spillover (β = −0.281, p < 0.001) emerged as significant protective factors against quiet quitting. Additionally, medico-legal experiences and consideration of leaving the profession were associated with increased disengagement. Quiet quitting may represent a clinically relevant manifestation of reduced motivation and occupational disengagement among physicians. Our findings highlight the need for integrated interventions targeting both structural work conditions and individual psychological resources to mitigate disengagement and support sustainable workforce well-being in healthcare systems.
- Open Access
- 18 March 2026
- Published by Springer Nature in BMC Women's Health
- Vol. 26 (1)
Independent role of alexithymia on weight loss outcomes in obese women: a six month follow-up study
The relationship between difficulties in emotion regulation and obesity has received a great deal of attention. This study aimed to investigate whether alexithymia affects the success of weight loss in obese women, and whether this is mediated by depression. This prospective longitudinal study was conducted at an obesity centre, where female patients were enrolled in a six-month diet and education programme. At the beginning of the programme, the Toronto Alexithymia Scale (TAS-20) and the Beck Depression Inventory (BDI) were used to assess levels of alexithymia and depression, respectively. Body mass index (BMI) was also calculated. At the end of six months, BMI was calculated again. The mediating role of the depressive symptoms in the association between the alexithymia and the rate of change in BMI(cBMI) was examined using the Process v4.2 package by Andrew F. Hayes, with model 4 being employed. The bootstrap method was used to test the indirect effect. The study included 49 obese women. There was a statistically significant negative correlation between cBMI and TAS-20 score at baseline (ρ= -0.756; p < 0.001), whereas there was no statistically significant correlation between BDI score and cBMI (ρ = 0.037; p = 0.802). In the regression model, alexithymia was independently associated with cBMI (p < 0.001), while depressive symptoms were not independently associated with changes in BMI (p = 0.690). The indirect effect of the TAS-20 score on cBMI via depression was not statistically significant. Higher levels of alexithymia were associated with poorer weight loss outcomes in obese women, independent of depressive symptom severity. The online version contains supplementary material available at 10.1186/s12905-026-04399-x.
- 18 March 2026
- Published by Springer Nature in BMC Women's Health
- Vol. 26 (1)
Open AccessIndependent role of alexithymia on weight loss outcomes in obese women: a six month follow-up study
The relationship between difficulties in emotion regulation and obesity has received a great deal of attention. This study aimed to investigate whether alexithymia affects the success of weight loss in obese women, and whether this is mediated by depression. This prospective longitudinal study was conducted at an obesity centre, where female patients were enrolled in a six-month diet and education programme. At the beginning of the programme, the Toronto Alexithymia Scale (TAS-20) and the Beck Depression Inventory (BDI) were used to assess levels of alexithymia and depression, respectively. Body mass index (BMI) was also calculated. At the end of six months, BMI was calculated again. The mediating role of the depressive symptoms in the association between the alexithymia and the rate of change in BMI(cBMI) was examined using the Process v4.2 package by Andrew F. Hayes, with model 4 being employed. The bootstrap method was used to test the indirect effect. The study included 49 obese women. There was a statistically significant negative correlation between cBMI and TAS-20 score at baseline (ρ= -0.756; p < 0.001), whereas there was no statistically significant correlation between BDI score and cBMI (ρ = 0.037; p = 0.802). In the regression model, alexithymia was independently associated with cBMI (p < 0.001), while depressive symptoms were not independently associated with changes in BMI (p = 0.690). The indirect effect of the TAS-20 score on cBMI via depression was not statistically significant. Higher levels of alexithymia were associated with poorer weight loss outcomes in obese women, independent of depressive symptom severity. The online version contains supplementary material available at 10.1186/s12905-026-04399-x.
- 20 December 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 397, 120979
Serum FGF21 and GDF15 levels and their association with cognitive function in bipolar disorder
- 20 December 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 397, 120979
Serum FGF21 and GDF15 levels and their association with cognitive function in bipolar disorder
- 8 November 2024
- Published by Springer Nature in Psychiatric Quarterly
- Vol. 96 (1) , 19-37
Are S100B and VILIP-1 Involved in a Common Mechanism of Neuroinflammation in Major Depressive Disorder?
This study aimed to evaluate the role of neuroinflammation in neuronal and glial cells in the pathophysiology of Major Depressive Disorder (MDD) through different biomarkers.S100-B and VILIP-1 levels of patients diagnosed with MDD were evaluated before and after antidepressant treatment. A total of 65 patients diagnosed with MDD and 69 healthy controls were included. Serum levels of S100B and VILIP-1 were measured at the time of diagnosis and after eight weeks antidepressant treatment and compared with healthy controls. Hamilton Depression Rating Scale (HDRS) and the Clinical Global Impression Scale (CGI) were applied to assess the severity of depression. In our study, although serum S100B levels were higher in patients before treatment compared to healthy controls, this difference was not statistically significant. Regarding VILIP-1 levels, there was no statistically significant difference between patients and healthy controls. A positive and statistically significant correlation was found between S100B and VILIP-1 levels in MDD group before the treatment. At the eighth week of treatment, a statistically significant positive correlation was also found between S100B and VILIP-1 levels. Our research is the first study to evaluate MDD through two separate biomarkers specific to glial and neuronal cells.The fact that S100B and VILIP-1 levels showed significant correlations in patients diagnosed with MDD both before and after treatment suggests that they may play a shared role in the pathophysiology of the disorder. The correlation between S100B and VILIP-1 may serve as a guide in understanding the pathophysiology of the disorder and in identifying new drug development targets.
- 8 November 2024
- Published by Springer Nature in Psychiatric Quarterly
- Vol. 96 (1) , 19-37
Are S100B and VILIP-1 Involved in a Common Mechanism of Neuroinflammation in Major Depressive Disorder?
This study aimed to evaluate the role of neuroinflammation in neuronal and glial cells in the pathophysiology of Major Depressive Disorder (MDD) through different biomarkers.S100-B and VILIP-1 levels of patients diagnosed with MDD were evaluated before and after antidepressant treatment. A total of 65 patients diagnosed with MDD and 69 healthy controls were included. Serum levels of S100B and VILIP-1 were measured at the time of diagnosis and after eight weeks antidepressant treatment and compared with healthy controls. Hamilton Depression Rating Scale (HDRS) and the Clinical Global Impression Scale (CGI) were applied to assess the severity of depression. In our study, although serum S100B levels were higher in patients before treatment compared to healthy controls, this difference was not statistically significant. Regarding VILIP-1 levels, there was no statistically significant difference between patients and healthy controls. A positive and statistically significant correlation was found between S100B and VILIP-1 levels in MDD group before the treatment. At the eighth week of treatment, a statistically significant positive correlation was also found between S100B and VILIP-1 levels. Our research is the first study to evaluate MDD through two separate biomarkers specific to glial and neuronal cells.The fact that S100B and VILIP-1 levels showed significant correlations in patients diagnosed with MDD both before and after treatment suggests that they may play a shared role in the pathophysiology of the disorder. The correlation between S100B and VILIP-1 may serve as a guide in understanding the pathophysiology of the disorder and in identifying new drug development targets.